| Literature DB >> 31838552 |
S N Morin1,2, M Djekic-Ivankovic3, L Funnell4, L Giangregorio5, I B Rodrigues5, R Ridout6, S Feldman6, S Kim6, H McDonald-Blumer6, G Kline7, W E Ward8, N Santesso9, W D Leslie10.
Abstract
Patient engagement in clinical guidelines development is essential. The results of a self-administered online survey identified themes important to people living with osteoporosis and will inform the development of Osteoporosis Canada clinical guidelines recommendations.Entities:
Keywords: Clinical guidelines; Osteoporosis; Patient engagement; Survey
Mesh:
Year: 2019 PMID: 31838552 PMCID: PMC7170816 DOI: 10.1007/s00198-019-05248-4
Source DB: PubMed Journal: Osteoporos Int ISSN: 0937-941X Impact factor: 4.507
Survey participants’ characteristics
| Participants’ characteristics | |
|---|---|
| Sex, | |
| Women | 1059 (96%) |
| Language, | |
| English | 1036 (94%) |
| Osteoporosis, | |
| I have OP | 943 (86%) |
| I care for someone with OP | 29 (3%) |
| Place of residence of participants in Canada (%) | |
| Western Canada | 34% |
| Central Canada | 58% |
| Atlantic Canada | 8% |
| Northern Canada | < 1% |
| Osteoporosis knowledge (%) | |
| Knowledgeable1 | 85% |
| Not knowledgeable2 | 15% |
1Knowledgeable includes very knowledgeable and knowledgeable; 2Not knowledgeable includes little knowledgeable, very little knowledgeable, or neutral
Fig. 1Percentage of respondents who indicated that specific recommendations (a) and outcomes (b) were critical to consider in the updated osteoporosis clinical guideline development
Participants’ responses to the open-ended question: What questions do you have about the safety or effectiveness of exercise, or safe performance of physical activities of leisure or daily living?
| Number of participants who provided answers | |
|---|---|
| Total references* | |
| How can I exercise safely? | 222 |
Safety of specific/preferred exercises (yoga etc.) What exercises to avoid What exercises/classes/movements are safe to do Concerns about adverse effects (including pain) If I have a vertebral fracture | 69 56 53 31 14 |
| How can I exercise effectively? | 145 |
Best/most effective exercises for my condition Right frequency/duration/intensity of exercise/strength training | 88 57 |
| How can I access safe and effective exercises? | 116 |
Trained professionals Make adapted exercises available online/on video/at home Community/support groups/age-specific classes | 48 35 33 |
| What are the benefits of exercise on: | 72 |
Bone mineral density Fracture risk Balance and strength Pain and quality of life improvement | 23 23 15 11 |
| Other | 31 |
*Each participant could give more than one idea: 1 idea = 1 reference. Total indicates the number of references among the participants who answered the open-ended question
Participants’ responses to the open-ended question: What questions or issues related to medications for osteoporosis would you like to see addressed in the next Canadian Osteoporosis Clinical Practice Guidelines in order to help doctors and other healthcare professionals in making treatment decisions with their patients?
| Number of participants who provided answers | |
|---|---|
| Total references* | |
| Pharmacologic treatment | 75 |
| Benefits and harms | 55 |
| Cost of medications | 7 |
| Drug-drug interactions | 5 |
| New medications | 4 |
| Drug holiday | 2 |
| Access to medications | 1 |
| Time to start with a therapy | 1 |
| Nutrition and supplements | 19 |
| Supplements recommendations | 12 |
| Dietary recommendations | 7 |
| Alternative therapies | 14 |
| Education | 11 |
| For patients/families/caregivers—source of information they can trust | 6 |
| For healthcare professionals | 5 |
| Monitoring-prevention | 8 |
| Response to treatment/BMD | 6 |
| Prevention | 1 |
| Access to specialists | 1 |
| Pain management | 6 |
| Other | 2 |
*Each participant could give more than one idea: 1 idea = 1 reference. Total indicates the number of references among the participants who answered the open-ended question
Participants’ responses to the open-ended question: Provide up to three specific questions you would like to see addressed in the next Canadian Osteoporosis Clinical Practice Guidelines
| Number of participants who provided answers | |
|---|---|
| Total references* | |
| Pharmacological treatment | 327 |
| Benefits and harms | 183 |
| New medications/the best medication | 58 |
| Duration of therapy/drug holiday | 54 |
| Other (cost, medication choice, etc.) | 32 |
| Screening-monitoring-prevention | 193 |
| BMD tests/response to treatment | 88 |
| Prevention | 65 |
| Early screening | 30 |
| Other (access to specialists, clinics, etc.) | 10 |
| Nutrition and supplements | 140 |
| Dietary recommendations | 59 |
| Supplements recommendations | 52 |
| Dietary sources of calcium | 22 |
| Other (vitamin K, protein) | 7 |
| Exercise-physical activity | 121 |
| Recommendations | 80 |
| Safety and benefits | 31 |
| Other (fit trainers, cost, etc.) | 10 |
| Knowledge-education-advocacy | 135 |
| Patients/families/caregivers | 72 |
| Healthcare professionals | 22 |
| Advocacy/support groups | 17 |
| General public | 13 |
| Other (list of specialists, funding, etc.) | 11 |
| Alternative therapies | 30 |
| Naturopathy/natural products | 28 |
| Other | 2 |
| Pain | 18 |
| Pain management | 15 |
| Cannabis | 2 |
| Other (osteoporosis pain vs. arthritis pain) | 1 |
*Each participant could give more than one idea: 1 idea = 1 reference. Total indicates the number of references among the participants who answered the open-ended question